BeOne Medicines (ONC) – Investment Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for BeOne Medicines (NASDAQ: ONC):

• 10/16/2026 – BeOne Medicines had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $425.00 price target on the stock.
• 10/8/2026 – BeOne Medicines was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 10/8/2026 – BeOne Medicines had its price target raised by Royal Bank Of Canada from $450.00 to $459.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – BeOne Medicines had its price target raised by Truist Financial Corporation from $418.00 to $420.00. They now have a “buy” rating on the stock.
• 10/5/2026 – BeOne Medicines was downgraded by Zacks Research from “strong-buy” to “hold”.
• 10/1/2026 – BeOne Medicines had its price target raised by JPMorgan Chase & Co. from $425.00 to $445.00. They now have an “overweight” rating on the stock.
• 9/22/2026 – BeOne Medicines was upgraded by Weiss Ratings from “sell (d-)” to “hold (c+)”.
• 9/10/2026 – BeOne Medicines had its price target raised by Barclays PLC from $407.00 to $415.00. They now have an “overweight” rating on the stock.

Insider Activity at BeOne Medicines

In related news, CFO Aaron Rosenberg sold 1,157 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $312.71, for a total value of $361,805.47. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 115,011 shares of BeOne Medicines stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $357.87, for a total value of $41,158,986.57. Following the completion of the sale, the chief executive officer owned 125,799 shares in the company, valued at approximately $45,019,688.13. The trade was a 47.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 457,259 shares of company stock worth $158,876,315 in the last quarter. Company insiders own 6.19% of the company’s stock.

BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors.

Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers.